» Articles » PMID: 33574569

Mutations in Key Driver Genes of Pancreatic Cancer: Molecularly Targeted Therapies and Other Clinical Implications

Overview
Specialty Pharmacology
Date 2021 Feb 12
PMID 33574569
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a minimal difference between its incidence rate and mortality rate. Advances in oncology over the past several decades have dramatically improved the overall survival of patients with multiple cancers due to the implementation of new techniques in early diagnosis, therapeutic drugs, and personalized therapy. However, pancreatic cancers remain recalcitrant, with a 5-year relative survival rate of <9%. The lack of measures for early diagnosis, strong resistance to chemotherapy, ineffective adjuvant chemotherapy and the unavailability of molecularly targeted therapy are responsible for the high mortality rate of this notorious disease. Genetically, PDAC progresses as a complex result of the activation of oncogenes and inactivation of tumor suppressors. Although next-generation sequencing has identified numerous new genetic alterations, their clinical implications remain unknown. Classically, oncogenic mutations in genes such as KRAS and loss-of-function mutations in tumor suppressors, such as TP53, CDNK2A, DPC4/SMAD4, and BRCA2, are frequently observed in PDAC. Currently, research on these key driver genes is still the main focus. Therefore, studies assessing the functions of these genes and their potential clinical implications are of paramount importance. In this review, we summarize the biological function of key driver genes and pharmaceutical targets in PDAC. In addition, we conclude the results of molecularly targeted therapies in clinical trials and discuss how to utilize these genetic alterations in further clinical practice.

Citing Articles

Inflammatory Stimuli and Fecal Microbiota Transplantation Accelerate Pancreatic Carcinogenesis in Transgenic Mice, Accompanied by Changes in the Microbiota Composition.

Swidnicka-Siergiejko A, Daniluk J, Miniewska K, Daniluk U, Guzinska-Ustymowicz K, Pryczynicz A Cells. 2025; 14(5).

PMID: 40072088 PMC: 11898920. DOI: 10.3390/cells14050361.


Loss of increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration.

Kannen V, Rasmussen M, Das S, Giuliana P, Izzati F, Choksi H Front Immunol. 2025; 15:1513595.

PMID: 39867896 PMC: 11759301. DOI: 10.3389/fimmu.2024.1513595.


The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment.

Matykiewicz J, Adamus-Bialek W, Wawszczak-Kasza M, Molasy B, Kolomanska M, Oblap R Sci Rep. 2025; 15(1):1791.

PMID: 39805914 PMC: 11729861. DOI: 10.1038/s41598-025-86249-8.


Identification of ferroptosis-related signature predicting prognosis and therapeutic responses in pancreatic cancer.

Chung T, Piao Z, Lee S Sci Rep. 2025; 15(1):75.

PMID: 39748113 PMC: 11695983. DOI: 10.1038/s41598-024-84607-6.


Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance.

Li S, Lin Y, Gao X, Zeng D, Cen W, Su Y Front Immunol. 2024; 15:1517312.

PMID: 39712016 PMC: 11659151. DOI: 10.3389/fimmu.2024.1517312.


References
1.
Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

2.
Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

3.
Neoptolemos J, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer D . Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018; 15(6):333-348. DOI: 10.1038/s41575-018-0005-x. View

4.
Maisonneuve P . Epidemiology and burden of pancreatic cancer. Presse Med. 2019; 48(3 Pt 2):e113-e123. DOI: 10.1016/j.lpm.2019.02.030. View

5.
Rawla P, Sunkara T, Gaduputi V . Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1):10-27. PMC: 6396775. DOI: 10.14740/wjon1166. View